Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cronos Group Inc (CRON)

Cronos Group Inc (CRON)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,204,795
  • Shares Outstanding, K 348,860
  • Annual Sales, $ 23,750 K
  • Annual Income, $ 1,167 M
  • 60-Month Beta 1.89
  • Price/Sales 81.91
  • Price/Cash Flow 8.13
  • Price/Book 1.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.06
  • Number of Estimates 4
  • High Estimate -0.03
  • Low Estimate -0.07
  • Prior Year -0.01
  • Growth Rate Est. (year over year) -500.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.82 +8.59%
on 06/29/20
7.28 -13.19%
on 06/11/20
-1.27 (-16.73%)
since 06/10/20
3-Month
4.62 +36.80%
on 05/14/20
8.13 -22.26%
on 06/09/20
+0.53 (+9.15%)
since 04/09/20
52-Week
4.00 +58.00%
on 03/16/20
15.85 -60.13%
on 07/11/19
-8.97 (-58.67%)
since 07/10/19

Most Recent Stories

More News
Cronos Group Announces Completion of Continuance to British Columbia

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group" or the "Company") announces that, effective today, the Company has continued from the laws of the Province of Ontario to the laws of the Province...

CRON : 6.32 (+4.98%)
CRON.TO : 8.60 (+4.75%)
Cronos Group Inc. to Hold 2020 Second Quarter Earnings Conference Call on August 6, 2020

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group" or the "Company") will hold its 2020 Second Quarter Earnings Conference Call on Thursday, August 6, 2020 at 8:30 a.m. EDT. Cronos Group's senior...

CRON : 6.32 (+4.98%)
CRON.TO : 8.60 (+4.75%)
While FDA Advances Work Related to Cannabidiol Products CBD Usage Rates are on the Rise

, /PRNewswire/ -- Just a few years ago, not many people knew what CBD is… or does. Things have really changed so much so that now, it's harder to find someone who does know what it is! A recent report...

RTSL : 1.7899 (+43.19%)
CRON : 6.32 (+4.98%)
CRON.TO : 8.60 (+4.75%)
CGC : 17.42 (+8.74%)
WEED.TO : 23.66 (+8.14%)
CVSI : 0.6100 (+8.91%)
VFF : 5.10 (+2.62%)
VFF.TO : 6.91 (+3.13%)
Cronos Group Inc. Announces Results of 2020 Annual and Special Meeting of Shareholders

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group" or the "Company") announces that at its Annual and Special Meeting of Shareholders held earlier today (the "Meeting") there were 652 shareholders...

CRON : 6.32 (+4.98%)
CRON.TO : 8.60 (+4.75%)
Rise In CBD and CBG's Popularity Driven By Combination Of Non-Psychoactive Nature and Therapeutic Properties

Palm Beach, FL - June 23, 2020 - The cannabis plant is made up of more than 100 unique chemical compounds, known as cannabinoids. So far, the two most common and well-known cannabinoids are tetrahydrocannabinol...

FMAX : N/A (unch)
RTSL : 1.7899 (+43.19%)
ACB : 12.02 (+2.12%)
ACB.TO : 16.33 (+1.81%)
NEPT : 3.11 (-3.72%)
NEPT.TO : 4.26 (-3.18%)
CRON : 6.32 (+4.98%)
CRON.TO : 8.60 (+4.75%)
CVSI : 0.6100 (+8.91%)
Rise in CBD and CBG's Popularity Driven By Combination of Non-psychoactive Nature and Therapeutic Properties

, /PRNewswire/ -- The cannabis plant is made up of more than 100 unique chemical compounds, known as cannabinoids. So far, the two most common and well-known cannabinoids are tetrahydrocannabinol (THC)...

RTSL : 1.7899 (+43.19%)
ACB : 12.02 (+2.12%)
ACB.TO : 16.33 (+1.81%)
NEPT : 3.11 (-3.72%)
NEPT.TO : 4.26 (-3.18%)
CRON : 6.32 (+4.98%)
CRON.TO : 8.60 (+4.75%)
CVSI : 0.6100 (+8.91%)
COVID Spikes a Tsunami of Cannabis Sales

, /PRNewswire/ --Strange bedfellows, COVID-19 and cannabis. As the pandemic wreaked havoc on the U.S. and global economies, cannabis sales rocketed higher across multiple markets in North America. California...

ACB.TO : 16.33 (+1.81%)
CGC : 17.42 (+8.74%)
CRON : 6.32 (+4.98%)
ACB : 12.02 (+2.12%)
OGI : 1.5300 (+2.68%)
NUGS : 0.0860 (-3.26%)
Is it Time to Buy Cannabis Stocks & ETFs?

CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.

GWPH : 127.90 (-0.16%)
IBUY : 77.97 (+0.78%)
IIPR : 90.78 (+1.15%)
CGC : 17.42 (+8.74%)
CRON : 6.32 (+4.98%)
CNBS : 11.37 (+2.29%)
Cannabis Sales Turning a New Leaf Expected to Top $30 Billion Annually Within the Next Four Years

, /PRNewswire/ -- Cannabis companies have experienced a rapid growth phase for years. Industry reports say that the COVID-19 outbreak is causing serious jitters among large cannabis companies, with a growing...

CRON.TO : 8.60 (+4.75%)
NUGS : 0.0860 (-3.26%)
CGC : 17.42 (+8.74%)
WEED.TO : 23.66 (+8.14%)
CRON : 6.32 (+4.98%)
OGI : 1.5300 (+2.68%)
OGI.TO : 2.08 (+3.48%)
MJNA : 0.0164 (+2.50%)
Easing Regulations Place Psychedelic Medical Products on the Path to Growth

, /PRNewswire/ -- In just a few years, the perception about psychedelics and their possible uses has started to shift from a potentially dangerous party drug to an approachable medicinal product. For...

XXII : 0.7558 (-2.57%)
NUMI.VN : 0.320 (+3.23%)
LKYSD : 0.3330 (+17.54%)
CRON : 6.32 (+4.98%)
GTBIF : 11.2900 (+9.66%)
CWBHF : 3.8150 (+6.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade CRON with:

Business Summary

Cronos Group, Inc. engages in the investment in firms which are licensed to produce and sell medical marijuana. Its portfolio includes In The Zone, Peace Naturals, Whistler Medical Marijuana Co., ABcann, Hydropothecary, Vert Medical and Evergreen Medicinal Supply. Cronos Group Inc., formerly known as...

See More

Key Turning Points

2nd Resistance Point 6.63
1st Resistance Point 6.48
Last Price 6.32
1st Support Level 6.09
2nd Support Level 5.85

See More

52-Week High 15.85
Fibonacci 61.8% 11.32
Fibonacci 50% 9.93
Fibonacci 38.2% 8.53
Last Price 6.32
52-Week Low 4.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar